Esomeprazole + Lansoprazole + Pantoprazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Heartburn
Conditions
Heartburn, Upper Abdominal Pain, Nausea, Acid Regurgitation
Trial Timeline
Jun 1, 2004 → Nov 1, 2004
NCT ID
NCT00625274About Esomeprazole + Lansoprazole + Pantoprazole
Esomeprazole + Lansoprazole + Pantoprazole is a approved stage product being developed by AstraZeneca for Heartburn. The current trial status is completed. This product is registered under clinical trial identifier NCT00625274. Target conditions include Heartburn, Upper Abdominal Pain, Nausea.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00625274 | Approved | Completed |
Competing Products
20 competing products in Heartburn